Ευρωπαϊκή Ένωση - Λετονικά - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrela hidrohlorīds - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiskie līdzekļi - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Λετονία - Λετονικά - Zāļu valsts aģentūra

mylan pharmaceuticals limited, ireland - erlotinibs - apvalkotā tablete - 100 mg

Λετονία - Λετονικά - Zāļu valsts aģentūra

mylan pharmaceuticals limited, ireland - ivabradīns - apvalkotā tablete - 5 mg

Λετονία - Λετονικά - Zāļu valsts aģentūra

mylan pharmaceuticals limited, ireland - ivabradīns - apvalkotā tablete - 7,5 mg

Λετονία - Λετονικά - Zāļu valsts aģentūra

mylan pharmaceuticals limited, ireland - erlotinibs - apvalkotā tablete - 150 mg

Λετονία - Λετονικά - Zāļu valsts aģentūra

mylan s.a.s, france - aripiprazols - tablete - 10 mg

Λετονία - Λετονικά - Zāļu valsts aģentūra

mylan s.a.s, france - aripiprazols - tablete - 15 mg

Λετονία - Λετονικά - Zāļu valsts aģentūra

mylan pharmaceuticals limited, ireland - bimatoprostum, timololum - acu pilieni, šķīdums - 0,3 mg/5 mg/ml

Λετονία - Λετονικά - Zāļu valsts aģentūra

mylan pharmaceuticals limited, ireland - agomelatīns - apvalkotā tablete - 25 mg

Ευρωπαϊκή Ένωση - Λετονικά - EMA (European Medicines Agency)

mylan pharmaceuticals limited - emtricitabine, tenofovir disoproxil maleāts - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - treatment of hiv-1 infection:emtricitabine/tenofovir disoproxil mylan is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults (see section 5. emtricitabine/tenofovir disoproxil mylan is also indicated for the treatment of hiv-1 infected adolescents, with nrti resistance or toxicities precluding the use of first line agents, (see sections 4. 2, 4. 4 un 5. pre-exposure prophylaxis (prep):emtricitabine/tenofovir disoproxil mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults and adolescents at high risk (see sections 4. 2, 4. 4 un 5.